Establishment Labs (NASDAQ: ESTA) posts J.P. Morgan conference presentation

Rhea-AI Filing Summary

Establishment Labs Holdings Inc. filed a Form 8-K to share that it presented at the J.P. Morgan Healthcare Conference on January 14, 2026. The company is furnishing, rather than filing, the investor presentation as Exhibit 99.1, meaning it is not subject to certain liability provisions that apply to filed information.

The report highlights that the materials may contain forward-looking statements and preliminary financial data prepared by management. The company notes that its independent registered public accounting firm, CBIZ, Inc., has not audited, reviewed, or provided any assurance on this preliminary financial information, so it should not be relied on as a substitute for full GAAP financial statements.

0001688757false00016887572026-01-142026-01-140001688757dei:FormerAddressMember2026-01-142026-01-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

January 14, 2026

Date of Report (date of earliest event reported)

Establishment Labs Holdings Inc.

(Exact name of registrant as specified in its charter)

British Virgin Islands

001-38593

98-1436377

(State or other jurisdiction of incorporation or organization)

(Commission File No.)

(I.R.S. Employer Identification Number)

11401 Century Oaks Terrace Suite 400 Austin, Texas 78758

(Address of principal executive offices) (Zip Code)

+ 1 800 924-5072

(Registrant’s telephone number, including area code)

Building B23 and B25 Coyol Free Zone Alajuela Costa Rica

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol			Name of each exchange on which registered
Common Shares, No Par Value			ESTA			The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2) of this chapter.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On January 14, 2026, Establishment Labs (the "Company") presented at the J.P. Morgan Healthcare Conference.

The Company is furnishing presentation materials included as Exhibit 99.1 to this report pursuant to Item 7.01 of Form 8-K. The Company is not undertaking to update this presentation.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibit 99.1).

Special Note Regarding Forward-Looking Statements

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,

as amended, and Section 21E of the Securities Exchange Act of 1934, as amended or the Exchange Act. These estimates should not be viewed as a substitute for our full interim or annual financial statements prepared in accordance with U.S. generally accepted accounting principles. Accordingly, you should not place undue reliance on this preliminary data. The preliminary financial data has been prepared by, and is the responsibility of, our management. CBIZ, Inc., our independent registered public accounting firm, has not audited, reviewed, compiled or performed any procedures with respect to the accompanying preliminary financial data. Accordingly, CBIZ, Inc. does not express an opinion or any other form of assurance with respect thereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.			Description
99.1			Presentation materials dated January 14, 2026
104			Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

ESTABLISHMENT LABS HOLDINGS INC.

Dated:

January 14, 2026

By:

/s/ Rajbir S. Denhoy

Name:

Rajbir S. Denhoy

Title:

Chief Financial Officer

FAQ

What did Establishment Labs (ESTA) report in this Form 8-K?

Establishment Labs Holdings Inc. reported that it presented at the J.P. Morgan Healthcare Conference on January 14, 2026 and made the related presentation materials available as Exhibit 99.1.

What is included in Exhibit 99.1 for ESTA?

Exhibit 99.1 consists of Establishment Labs’ presentation materials dated January 14, 2026 that were used at the J.P. Morgan Healthcare Conference.

Is the Establishment Labs conference presentation considered filed with the SEC?

The company states that the information in this report, including Exhibit 99.1, is being furnished under Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act.

Does the ESTA 8-K contain forward-looking statements or preliminary financial data?

Yes. The report notes that it contains forward-looking statements and references preliminary financial data that should not be viewed as a substitute for full GAAP financial statements.

Has CBIZ, Inc. audited or reviewed the preliminary financial data mentioned by Establishment Labs?

No. The company explains that CBIZ, Inc., its independent registered public accounting firm, has not audited, reviewed, compiled, or performed procedures on the preliminary financial data and does not express any opinion or assurance on it.

Who signed the Establishment Labs Form 8-K related to the J.P. Morgan conference?

The Form 8-K was signed on behalf of Establishment Labs Holdings Inc. by Rajbir S. Denhoy, the company’s Chief Financial Officer.